RareSearch logo

BioLamina

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Albert Shanahan profile

Albert Shanahan

🇲🇽 Mexico

9.3

    Reviewed:

  • - Market Access Strategy
  • - 6 weeks January - February 2024
  • - Pharmaceutical Company

Strategic market access analysis, insightful recommendations.

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Shannon Harvey profile

Shannon Harvey

🇧🇷 Brazil

9

    Reviewed:

  • - Clinical Protocol Design
  • - 6 weeks April - May 2023
  • - Pharmaceutical Company

Comprehensive protocol design, very detailed and precise.

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Kristine Thompson profile

Kristine Thompson

🇨🇦 Canada

8.7

    Reviewed:

  • - Patient Recruitment
  • - 8 weeks March - April 2023
  • - Clinical Research Organization

Highly effective patient recruitment strategies, project completed on time.

The patient recruitment strategies were highly effective, and the project was completed within the agreed timeframe. The team was very professional, and their expertise in patient engagement was evident throughout.

Pam Bernier profile

Pam Bernier

🇪🇸 Spain

9

    Reviewed:

  • - Process Development
  • - 12 weeks March - May 2024
  • - Biotech Company

Expert process development, enhanced efficiency.

The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.

Marvin Swift profile

Marvin Swift

🇨🇦 Canada

6

    Reviewed:

  • - Health Technology Assessment
  • - 8 weeks July - September 2024
  • - Pharmaceutical Company

Health technology assessment was superficial, lacked thorough analysis.

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.